The Hidden Link Between Inflammation and Cholesterol | Behind the Breakthrough
•February 23, 2026
0
Why It Matters
Targeting the inflammatory axis of cholesterol handling could transform cardiovascular therapy and open avenues for treating autoimmune disorders, delivering broader health and economic benefits.
Key Takeaways
- •Plaque buildup driven by chronic inflammation, not just cholesterol
- •Macrophages trap cholesterol via bacterial receptors, triggering inflammation
- •microRNA miR‑33 regulates cholesterol efflux, a therapeutic target
- •Inhibiting miR‑33 may reverse plaque and raise HDL levels
- •Findings extend to autoimmune diseases like lupus and psoriasis
Summary
The video explains that atherosclerotic plaque is primarily driven by chronic inflammation rather than merely cholesterol accumulation, highlighting a paradigm shift in heart‑disease research.
Researchers at NYU Langone discovered that macrophages ingest cholesterol using receptors meant for bacteria, which stalls the cells and launches an inflammatory cascade. The microRNA miR‑33 was identified as a key regulator that suppresses genes needed for cholesterol efflux, and experimental inhibitors of miR‑33 restored cholesterol removal and raised HDL levels in animal models.
“When the macrophage tries to clear cholesterol it gets stuck, and that’s when inflammation starts,” the speaker noted, adding that the same pathway appears relevant in autoimmune conditions such as lupus and psoriasis. He praised NYU’s collaborative environment for accelerating these breakthroughs.
If miR‑33 inhibitors can safely reverse plaque in humans, they could complement or replace statins, offering a new therapeutic class that tackles both lipid burden and vascular inflammation, with potential spill‑over benefits for other immune‑mediated diseases.
Original Description
Heart disease has long been treated like a plumbing problem—arteries clogged with cholesterol. But Kathryn Moore, PhD, helped reveal something far more complex: the body’s own immune system may be driving the damage.
In this episode of Behind the Breakthrough, Dr. Moore, director of the Cardiovascular Research Center at NYU Langone Health, explains how her lab uncovered inflammatory pathways that cause plaque to grow—and how targeting those pathways could lead to therapies that don’t just slow heart disease, but potentially reverse it.
Her research focuses on immune cells called macrophages, which attempt to clear cholesterol but instead can become trapped, triggering chronic inflammation. One of her lab’s key discoveries involved miR-33, a genetic regulator that blocks the body’s ability to remove excess cholesterol. By inhibiting miR-33, her team demonstrated a new strategy to restore the body’s natural ability to clear plaque.
“We discovered that it’s actually the body’s immune response to accumulating cholesterol,” Dr. Moore explains. “It’s a chronic inflammation that causes plaque to grow with time."
These findings helped redefine heart disease as an immune-driven condition—and point toward therapies that could shrink disease at its source.
Dr. Moore’s journey illustrates how fundamental discoveries can transform medicine. “I love coming to work every day and discovering something new,” she says. “Every day is a new journey.”
Chapters:
00:00 Intro: Rethinking heart disease beyond cholesterol
00:32 The immune system’s role in plaque buildup
01:05 How inflammation drives atherosclerosis
01:35 MicroRNA and new treatment targets
02:05 From lab discovery to future therapies
02:35 What this means for heart disease treatment
Learn about our featured researcher: Kathryn Moore, PhD
Learn about the Cardiovascular Research Center
0
Comments
Want to join the conversation?
Loading comments...